Core Scientific (CORZR) Cash & Equivalents (2021 - 2026)

Core Scientific's Cash & Equivalents history runs 6 years deep, the most recent figure standing at $1.0 billion for Q1 2026.

• In Q1 2026, Cash & Equivalents rose 44.02% year-over-year to $1.0 billion; the TTM figure through Mar 2026 stood at $1.0 billion (up 44.02% YoY), while the FY2025 annual figure was $311.4 million, down 62.76% from the prior year.
• Cash & Equivalents came in at $1.0 billion for Q1 2026 at Core Scientific, up from $311.4 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $1.0 billion in Q1 2026 to a low of $15.9 million in Q4 2022.
• A 5-year average of $282.4 million and a median of $98.1 million in 2024 frame the typical range for Cash & Equivalents.
• On a YoY basis, Cash & Equivalents climbed as much as 6186.29% in 2022 and fell as far as 86.52% in 2022.
• Core Scientific's Cash & Equivalents stood at $15.9 million in 2022, then surged by 217.36% to $50.4 million in 2023, then surged by 1558.83% to $836.2 million in 2024, then sank by 62.76% to $311.4 million in 2025, then surged by 222.81% to $1.0 billion in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $1.0 billion, $311.4 million, and $453.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison